Revolution Medicines, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Revolution Medicines is a clinical-stage precision oncology company developing therapies for RAS-addicted cancers; it has no products approved for sale and has not generated product-sales revenue.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Revenue | $0 | $7.0 million |
| Research and development expense | $118.0 million | $68.9 million |
| General and administrative expense | $22.8 million | $13.2 million |
| Operating loss | $140.9 million | $75.2 million |
| Net loss | $116.0 million | $68.1 million |
| Net loss per share, basic and diluted | $0.70 | $0.72 |
| Cash and cash equivalents plus marketable securities | $1.704 billion | $1.853 billion at December 31, 2023 |
| Operating cash used | $160.6 million | $62.4 million |
| Total liabilities | $182.9 million | $235.5 million at December 31, 2023 |
With no revenue in Q1, profit and operating margins are not meaningful. Cash, cash equivalents and marketable securities fell by approximately $149 million from year-end. Cash and cash equivalents alone were $288.4 million; marketable securities were $1.415 billion. The company reported no borrowings; operating lease liabilities totaled $88.0 million, with $143.7 million of undiscounted future lease payments. Accumulated deficit was $1.254 billion.
Changes and cash flows
- Revenue fell by $7.0 million because the Sanofi collaboration agreement had terminated in June 2023.
- R&D expense rose $49.1 million, or 71%, led by increased RMC-6236 clinical and supply costs, higher personnel expense, preclinical spending, and costs for RMC-6291 and RMC-9805.
- G&A expense increased $9.6 million, or 73%, reflecting higher headcount, stock-based compensation, facilities, pre-commercial activity, and professional fees.
- Interest income increased to $23.8 million from $7.1 million, primarily because of the larger investment balance and higher rates.
- Operating cash use increased to $160.6 million. Investing cash use was $248.0 million, primarily reflecting purchases of marketable securities exceeding maturities; financing provided $0.8 million, with no ATM shares sold during the quarter.
Outlook, commentary and risks
- Management expects existing cash, cash equivalents and marketable securities to fund planned operations for at least 12 months after the financial statements’ issuance. It expects expenses, particularly R&D, to increase and states that substantial additional funding will be needed for continued development and potential commercialization; financing may not be available on acceptable terms.
- The company expected to initiate randomized registrational trials of RMC-6236 in previously treated pancreatic cancer and RAS-mutated non-small cell lung cancer in the second half of 2024, subject to regulatory feedback. Updated RMC-6236 monotherapy data and initial combination data were also expected in the second half of 2024.
- Management described interim clinical observations for RMC-6236, RMC-6291 and RMC-9805 as preliminary. The filing cautions that early or interim results may not predict later-stage outcomes; clinical development, regulatory approval, patient enrollment, manufacturing and competition remain significant risks.
- Unusual items included a $2.8 million impairment of a long-term asset acquired with EQRx and a $3.9 million non-cash gain from changes in the fair value of warrant liabilities and contingent earn-out shares.
- The company reported no litigation expected by management to have a material adverse effect, no material changes in internal control during the quarter, and no off-balance-sheet arrangements.
Key facts for investors to verify
- Whether the planned RMC-6236 registrational trials and anticipated 2024 data releases occurred on the stated timelines, and what the final clinical results show.
- How subsequent trial progress, enrollment, safety findings and regulatory feedback affect development plans and spending.
- Cash and investment balances, operating cash burn and management’s stated funding runway in later filings; runway is an estimate, not a guarantee.
- Whether the discontinued Sanofi collaboration is replaced by revenue-generating partnerships, and the potential dilution or other terms of future financing.
- Changes in lease commitments, contingent earn-out obligations, warrants and outstanding or reserved equity awards.